Positive results from Periostat/Atridox combination trial

CollaGenex Pharmaceuticals has reported clinically- andstatistically-significant findings from a six-month, 180-patient clinical study which investigated the safety and efficacy of Periostat (doxycycline hyclate tablets) in combination with Atridox (doxycycline) and scaling and root planing, versus SRP alone, for the treatment of periodontitis.

Participants entered the trial with eight diseased tooth areas and periodontal pocket depths of at least 5mm. On trial completion, patients in the Periostat/Atridox plus SRP group demonstrated a 48% mean improvement in clinical attachment level and a 44% mean reduction in periodontal pocket depths for pockets of 7mm or greater at baseline, compared to comparable pockets in volunteers in the SRP alone group.

The results, showing that the patients receiving the combination of treatments experienced more than a 2mm improvement in mean attachment gain and pocket depth reduction, were highly statistically-significant vs SRP alone (p=less than 0.0001 for both parameters), the firm said.